JPML Creates Federal Docket in Okla. For Herceptin Breach of Warranty Actions

WASHINGTON, D.C. — The Judicial Panel on Multidistrict Litigation has created a federal docket in Oklahoma for actions involving the breast cancer drug Herceptin (trastuzumab), finding centralization will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation.

In an April 7 order, the panel found the actions share factual questions arising from Genentech’s marketing and sales of the drug. Plaintiffs in the actions are oncology providers who accuse the drug maker of breaching its warranties regarding the amount, volume, or concentration of Herceptin that it sold them.

Judge Terence C. Kern …